Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Receivables - Other: 2015-2025

Historic Receivables - Other for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Sep 2025 value amounting to $3.7 million.

  • Syndax Pharmaceuticals' Receivables - Other rose 5.71% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 5.71%. This contributed to the annual value of $3.6 million for FY2024, which is 196.25% up from last year.
  • Syndax Pharmaceuticals' Receivables - Other amounted to $3.7 million in Q3 2025, which was up 1.96% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Receivables - Other ranged from a high of $13.1 million in Q2 2022 and a low of $158,000 during Q1 2022.
  • Over the past 3 years, Syndax Pharmaceuticals' median Receivables - Other value was $3.5 million (recorded in 2024), while the average stood at $2.7 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first soared by 2,925.87% in 2022, then plummeted by 95.92% in 2023.
  • Syndax Pharmaceuticals' Receivables - Other (Quarterly) stood at $429,000 in 2021, then skyrocketed by 709.79% to $3.5 million in 2022, then slumped by 64.68% to $1.2 million in 2023, then soared by 196.25% to $3.6 million in 2024, then climbed by 5.71% to $3.7 million in 2025.
  • Its Receivables - Other stands at $3.7 million for Q3 2025, versus $3.6 million for Q2 2025 and $3.6 million for Q1 2025.